{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:05:36Z","timestamp":1779527136798,"version":"3.53.1"},"reference-count":102,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>\n                    Delta-24\u2013based oncolytic viruses are conditional replication adenoviruses developed to selectively infect and replicate in retinoblastoma 1 (Rb)\u2013deficient cancer cells but not normal cell with intact Rb1 pathways. Over the years, there has been a significant evolution in the design of Delta-24 based on a better understanding of the underlying basis for infection, replication, and spread within cancer. One example is the development of Delta-24-RGD (DNX-2401), where the arginine-glycine-aspartate (RGD) domain enhances the infectivity of Delta-24 for cancer cells. DNX-2401 demonstrated objective biological and clinical responses during a phase I window of opportunity clinical trial for recurrent human glioblastoma. In long-term responders (&gt; 3 years), there was evidence of immune infiltration (T cells and macrophages) into the tumor microenvironment with minimal toxicity. Although more in-depth analysis and phase III studies are pending, these results indicate that Delta-24\u2013based adenovirus therapy may induce an antitumor response in glioblastoma, resulting in long-term antitumor immune response. In this review, the authors discuss the preclinical and clinical development of Delta-24 oncolytic adenoviral therapy for glioblastoma and describe structural improvements to Delta-24 that have enhanced its efficacy in vivo\n                    <jats:italic>.<\/jats:italic>\n                    They also highlight ongoing research that attempts to address the remaining obstacles limiting efficacy of Delta-24 adenovirus therapy for glioblastoma.\n                  <\/jats:p>","DOI":"10.3171\/2020.11.focus20853","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T06:43:52Z","timestamp":1612161832000},"page":"E6","source":"Crossref","is-referenced-by-count":26,"title":["Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations"],"prefix":"10.3171","volume":"50","author":[{"given":"Chibawanye I.","family":"Ene","sequence":"first","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fueyo","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"},{"name":"Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick F.","family":"Lang","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"24","key":"b1","series-title":"Oncotarget","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going viral: a review of replication-selective oncolytic adenoviruses","volume":"6","author":"Larson C","year":"2015","unstructured":"Larson C, Oronsky B, Scicinski J,  Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015;6(24):19976\u201319989.2628027710.18632\/oncotarget.5116"},{"key":"b2","series-title":"Oncolytic Virother","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/OV.S196403","article-title":"Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma","volume":"8","author":"Kiyokawa J","year":"2019","unstructured":"Kiyokawa J, Wakimoto H. Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma. Oncolytic Virother. 2019;8:27\u201337.10.2147\/OV.S19640331750274"},{"issue":"3","key":"b3","series-title":"Clin Transl Oncol","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12094-012-0951-7","article-title":"Viruses in cancer treatment","volume":"15","author":"Alemany R","year":"2013","unstructured":"Alemany R. Viruses in cancer treatment. Clin Transl Oncol. 2013;15(3):182\u2013188.2314395010.1007\/s12094-012-0951-7"},{"issue":"25","key":"b4","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka RH","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F,  Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20132788.10.1200\/JCO.2014.58.337726014293"},{"issue":"2","key":"b5","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins A","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE II,  Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150\u2013161.2994366610.1056\/NEJMoa1716435"},{"issue":"4","key":"b6","series-title":"Expert Rev Neurother","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1586\/ern.09.9","article-title":"Design and application of oncolytic HSV vectors for glioblastoma therapy","volume":"9","author":"Grandi P","year":"2009","unstructured":"Grandi P, Peruzzi P, Reinhart B,  Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother. 2009;9(4):505\u2013517.10.1586\/ern.09.919344302"},{"issue":"14","key":"b7","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang FF","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C,  Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419\u20131427.2943207710.1200\/JCO.2017.75.8219"},{"issue":"16","key":"b8","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-0349-03","article-title":"Use of replicating oncolytic adenoviruses in combination therapy for cancer","volume":"10","author":"Chu RL","year":"2004","unstructured":"Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 2004;10(16):5299\u20135312.1532816510.1158\/1078-0432.CCR-0349-03"},{"issue":"2","key":"b9","series-title":"Cell","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan CW","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A,  The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u2013477.10.1016\/j.cell.2013.09.03424120142"},{"issue":"1","key":"b10","series-title":"Oncogene","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo J","year":"2000","unstructured":"Fueyo J, Gomez-Manzano C, Alemany R,  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19(1):2\u201312.10.1038\/sj.onc.120325110644974"},{"key":"b11","series-title":"Mol Ther Methods Clin Dev","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos A","year":"2020","unstructured":"Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev. 2020;17:349\u2013358.3207192710.1016\/j.omtm.2020.01.001"},{"issue":"5304","key":"b12","series-title":"Science","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson JM","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G,  Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320\u20131323.903686010.1126\/science.275.5304.1320"},{"issue":"9","key":"b13","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo J","year":"2003","unstructured":"Fueyo J, Alemany R, Gomez-Manzano C,  Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95(9):652\u2013660.10.1093\/jnci\/95.9.652"},{"issue":"2","key":"b14","series-title":"Cell","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham TJ","year":"1993","unstructured":"Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73(2):309\u2013319.10.1016\/0092-8674(93)90231-E"},{"issue":"18","key":"b15","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/jnci\/djm102","article-title":"Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death","volume":"99","author":"Jiang H","year":"2007","unstructured":"Jiang H, Gomez-Manzano C, Aoki H,  Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007;99(18):1410\u20131414.1784867710.1093\/jnci\/djm102"},{"issue":"14","key":"b16","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang H","year":"2017","unstructured":"Jiang H, Rivera-Molina Y, Gomez-Manzano C,  Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017;77(14):3894\u20133907.10.1158\/0008-5472.CAN-17-046828566332"},{"issue":"1","key":"b17","series-title":"Neurooncol Adv","first-page":"vdz009","article-title":"GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory","volume":"1","author":"Rivera-Molina Y","year":"2019","unstructured":"Rivera-Molina Y, Jiang H, Fueyo J,  GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv. 2019;1(1):vdz009.31608328"},{"issue":"1","key":"b18","series-title":"Nat Commun","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Mart\u00ednez-V\u00e9lez N","year":"2019","unstructured":"Mart\u00ednez-V\u00e9lez N, Garcia-Moure M, Marigil M,  The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235.10.1038\/s41467-019-10043-031138805"},{"issue":"12","key":"b19","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/nm.3013","article-title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors","volume":"18","author":"Alvarez-Breckenridge CA","year":"2012","unstructured":"Alvarez-Breckenridge CA, Yu J, Price R,  NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 2012;18(12):1827\u20131834.2317824610.1038\/nm.3013"},{"issue":"19","key":"b20","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"9398","DOI":"10.1158\/0008-5472.CAN-07-1063","article-title":"Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses","volume":"67","author":"Fulci G","year":"2007","unstructured":"Fulci G, Dmitrieva N, Gianni D,  Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 2007;67(19):9398\u20139406.10.1158\/0008-5472.CAN-07-106317909049"},{"issue":"23","key":"b21","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"12846","DOI":"10.1073\/pnas.97.23.12846","article-title":"Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas","volume":"97","author":"Aboody KS","year":"2000","unstructured":"Aboody KS, Brown A, Rainov NG,  Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23):12846\u201312851.10.1073\/pnas.97.23.1284611070094"},{"issue":"1","key":"b22","series-title":"Expert Rev Neurother","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/14737175.6.1.1","article-title":"Targeted therapy for malignant glioma: neural stem cells","volume":"6","author":"Lesniak MS","year":"2006","unstructured":"Lesniak MS. Targeted therapy for malignant glioma: neural stem cells. Expert Rev Neurother. 2006;6(1):1\u20133.1646630510.1586\/14737175.6.1.1"},{"issue":"4","key":"b23","series-title":"J Clin Invest","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla J","year":"2019","unstructured":"Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Invest. 2019;129(4):1407\u20131418.10.1172\/JCI12228730829653"},{"issue":"23","key":"b24","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1158\/0008-5472.CAN-08-3873","article-title":"Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas","volume":"69","author":"Yong RL","year":"2009","unstructured":"Yong RL, Shinojima N, Fueyo J,  Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009;69(23):8932\u20138940.1992019910.1158\/0008-5472.CAN-08-3873"},{"issue":"3","key":"b25","series-title":"Stem Cells","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/stemcells.2007-0758","article-title":"Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma","volume":"26","author":"Sonabend AM","year":"2008","unstructured":"Sonabend AM, Ulasov IV, Tyler MA,  Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008;26(3):831\u2013841.1819223210.1634\/stemcells.2007-0758"},{"issue":"13","key":"b26","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/jnci\/djt141","article-title":"A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy","volume":"105","author":"Ahmed AU","year":"2013","unstructured":"Ahmed AU, Thaci B, Tobias AL,  A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst. 2013;105(13):968\u2013977.10.1093\/jnci\/djt14123821758"},{"issue":"2","key":"b27","series-title":"Gene Ther","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/gt.2008.165","article-title":"Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo","volume":"16","author":"Tyler MA","year":"2009","unstructured":"Tyler MA, Ulasov IV, Sonabend AM,  Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16(2):262\u2013278.1907899310.1038\/gt.2008.165"},{"issue":"11","key":"b28","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/mt.2013.179","article-title":"N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy","volume":"21","author":"Kim CK","year":"2013","unstructured":"Kim CK, Ahmed AU, Auffinger B,  N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol Ther. 2013;21(11):2063\u20132073.2388386310.1038\/mt.2013.179"},{"issue":"4","key":"b29","series-title":"Cytotherapy","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcyt.2017.02.002","article-title":"Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas","volume":"19","author":"Parker Kerrigan BC","year":"2017","unstructured":"Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy. 2017;19(4):445\u2013457.10.1016\/j.jcyt.2017.02.00228233640"},{"issue":"24","key":"b30","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"11499","DOI":"10.1158\/0008-5472.CAN-07-5312","article-title":"Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter","volume":"67","author":"Alonso MM","year":"2007","unstructured":"Alonso MM, Gomez-Manzano C, Bekele BN,  Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007;67(24):11499\u201311504.10.1158\/0008-5472.CAN-07-531218089777"},{"key":"b31","series-title":"Mol Ther Oncolytics","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.omto.2017.02.002","article-title":"The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8+T cell anti-tumor activity","volume":"5","author":"Kleijn A","year":"2017","unstructured":"Kleijn A, van den Bossche W, Haefner ES,  The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8+T cell anti-tumor activity. Mol Ther Oncolytics. 2017;5:11\u201319.10.1016\/j.omto.2017.02.00228480325"},{"issue":"16","key":"b32","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin J","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R,  Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u20131546.10.1056\/NEJMoa191083631562797"},{"issue":"3","key":"b33","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy TF","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR,  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477\u2013486.10.1038\/s41591-018-0337-730742122"},{"issue":"7","key":"b34","series-title":"JAMA Oncol","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon DA","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A,  Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003\u20131010.3243750710.1001\/jamaoncol.2020.1024"},{"issue":"1","key":"b35","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa AT","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A,  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84\u201388.10.1038\/nm151717159987"},{"issue":"7","key":"b36","series-title":"Trends Cancer","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan Q","year":"2020","unstructured":"Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605\u2013618.10.1016\/j.trecan.2020.02.02232610070"},{"issue":"1","key":"b37","series-title":"Brain Pathol","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1750-3639.2008.00234.x","article-title":"Genetically engineered mouse models of brain cancer and the promise of preclinical testing","volume":"19","author":"Huse JT","year":"2009","unstructured":"Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 2009;19(1):132\u2013143.10.1111\/j.1750-3639.2008.00234.x19076778"},{"issue":"1","key":"b38","series-title":"Cancer Gene Ther","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/cgt.2014.64","article-title":"A novel immunocompetent murine model for replicating oncolytic adenoviral therapy","volume":"22","author":"Zhang L","year":"2015","unstructured":"Zhang L, Hedjran F, Larson C,  A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Cancer Gene Ther. 2015;22(1):17\u201322.10.1038\/cgt.2014.6425525035"},{"issue":"4","key":"b39","series-title":"Cancer Gene Ther","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/cgt.2008.80","article-title":"Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats","volume":"16","author":"Sonabend AM","year":"2009","unstructured":"Sonabend AM, Ulasov IV, Han Y,  Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther. 2009;16(4):362\u2013372.10.1038\/cgt.2008.8019011597"},{"issue":"5","key":"b40","series-title":"PLoS One","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","author":"Jiang H","year":"2014","unstructured":"Jiang H, Clise-Dwyer K, Ruisaard KE,  Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014;9(5):e97407."},{"issue":"12","key":"b41","series-title":"Cell Rep","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.celrep.2019.02.063","article-title":"Modeling patient-derived glioblastoma with cerebral organoids","volume":"26","author":"Linkous A","year":"2019","unstructured":"Linkous A, Balamatsias D, Snuderl M,  Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep. 2019;26(12):3203\u20133211.e5.10.1016\/j.celrep.2019.02.06330893594"},{"issue":"7","key":"b42","series-title":"Cell","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal JT","year":"2018","unstructured":"Neal JT, Li X, Zhu J,  Organoid modeling of the tumor immune microenvironment. Cell. 2018;175(7):1972\u20131988.e16.10.1016\/j.cell.2018.11.02130550791"},{"issue":"505","key":"b43","series-title":"Sci Transl Med","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca EA","year":"2019","unstructured":"Chiocca EA, Yu JS, Lukas RV,  Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019;11(505):eaaw5680.3141314210.1126\/scitranslmed.aaw5680"},{"issue":"5","key":"b44","series-title":"PLoS One","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097495","article-title":"The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity","volume":"9","author":"Kleijn A","year":"2014","unstructured":"Kleijn A, Kloezeman J, Treffers-Westerlaken E,  The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS One. 2014;9(5):e97495.10.1371\/journal.pone.009749524866126"},{"issue":"3","key":"b45","series-title":"Biomedicines","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3390\/biomedicines4030013","article-title":"Tumor-associated macrophages in oncolytic virotherapy: friend or foe?","volume":"4","author":"Denton NL","year":"2016","unstructured":"Denton NL, Chen CY, Scott TR, Cripe TP. Tumor-associated macrophages in oncolytic virotherapy: friend or foe? Biomedicines. 2016;4(3):E13.10.3390\/biomedicines4030013"},{"key":"b46","article-title":"DNX-2401 with Interferon Gamma (IFN-\u03b3) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)","author":"Lang FF","unstructured":"Lang FF. DNX-2401 with Interferon Gamma (IFN-\u03b3) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I). Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02197169"},{"key":"b47","article-title":"Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM)","author":"Tejada S","unstructured":"Tejada S. Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM). Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01956734"},{"key":"b48","article-title":"Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients with Recurrent Glioblastoma","author":"Dirven C","unstructured":"Dirven C. Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients with Recurrent Glioblastoma. Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01582516"},{"key":"b49","article-title":"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas","author":"Gallego J","unstructured":"Gallego J. Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas. Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03178032"},{"key":"b50","article-title":"Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)","author":"Zadeh G","unstructured":"Zadeh G. Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02798406"},{"key":"b51","article-title":"Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma","author":"Lang FF","unstructured":"Lang FF. Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma. Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0389656829432077"},{"issue":"24","key":"b1","series-title":"Oncotarget","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going viral: a review of replication-selective oncolytic adenoviruses","volume":"6","author":"Larson C","year":"2015","unstructured":"Larson C, Oronsky B, Scicinski J,  Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015;6(24):19976\u201319989.2628027710.18632\/oncotarget.5116"},{"key":"b2","series-title":"Oncolytic Virother","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/OV.S196403","article-title":"Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma","volume":"8","author":"Kiyokawa J","year":"2019","unstructured":"Kiyokawa J, Wakimoto H. Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma. Oncolytic Virother. 2019;8:27\u201337.10.2147\/OV.S19640331750274"},{"issue":"3","key":"b3","series-title":"Clin Transl Oncol","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12094-012-0951-7","article-title":"Viruses in cancer treatment","volume":"15","author":"Alemany R","year":"2013","unstructured":"Alemany R. Viruses in cancer treatment. Clin Transl Oncol. 2013;15(3):182\u2013188.2314395010.1007\/s12094-012-0951-7"},{"issue":"25","key":"b4","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka RH","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F,  Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20132788.10.1200\/JCO.2014.58.337726014293"},{"issue":"2","key":"b5","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins A","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE II,  Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150\u2013161.2994366610.1056\/NEJMoa1716435"},{"issue":"4","key":"b6","series-title":"Expert Rev Neurother","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1586\/ern.09.9","article-title":"Design and application of oncolytic HSV vectors for glioblastoma therapy","volume":"9","author":"Grandi P","year":"2009","unstructured":"Grandi P, Peruzzi P, Reinhart B,  Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother. 2009;9(4):505\u2013517.10.1586\/ern.09.919344302"},{"issue":"14","key":"b7","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang FF","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C,  Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419\u20131427.2943207710.1200\/JCO.2017.75.8219"},{"issue":"16","key":"b8","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-0349-03","article-title":"Use of replicating oncolytic adenoviruses in combination therapy for cancer","volume":"10","author":"Chu RL","year":"2004","unstructured":"Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 2004;10(16):5299\u20135312.1532816510.1158\/1078-0432.CCR-0349-03"},{"issue":"2","key":"b9","series-title":"Cell","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan CW","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A,  The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u2013477.10.1016\/j.cell.2013.09.03424120142"},{"issue":"1","key":"b10","series-title":"Oncogene","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo J","year":"2000","unstructured":"Fueyo J, Gomez-Manzano C, Alemany R,  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19(1):2\u201312.10.1038\/sj.onc.120325110644974"},{"key":"b11","series-title":"Mol Ther Methods Clin Dev","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos A","year":"2020","unstructured":"Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev. 2020;17:349\u2013358.3207192710.1016\/j.omtm.2020.01.001"},{"issue":"5304","key":"b12","series-title":"Science","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson JM","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G,  Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320\u20131323.903686010.1126\/science.275.5304.1320"},{"issue":"9","key":"b13","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo J","year":"2003","unstructured":"Fueyo J, Alemany R, Gomez-Manzano C,  Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95(9):652\u2013660.10.1093\/jnci\/95.9.652"},{"issue":"2","key":"b14","series-title":"Cell","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham TJ","year":"1993","unstructured":"Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73(2):309\u2013319.10.1016\/0092-8674(93)90231-E"},{"issue":"18","key":"b15","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/jnci\/djm102","article-title":"Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death","volume":"99","author":"Jiang H","year":"2007","unstructured":"Jiang H, Gomez-Manzano C, Aoki H,  Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007;99(18):1410\u20131414.1784867710.1093\/jnci\/djm102"},{"issue":"14","key":"b16","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang H","year":"2017","unstructured":"Jiang H, Rivera-Molina Y, Gomez-Manzano C,  Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017;77(14):3894\u20133907.10.1158\/0008-5472.CAN-17-046828566332"},{"issue":"1","key":"b17","series-title":"Neurooncol Adv","first-page":"vdz009","article-title":"GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory","volume":"1","author":"Rivera-Molina Y","year":"2019","unstructured":"Rivera-Molina Y, Jiang H, Fueyo J,  GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv. 2019;1(1):vdz009.31608328"},{"issue":"1","key":"b18","series-title":"Nat Commun","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Mart\u00ednez-V\u00e9lez N","year":"2019","unstructured":"Mart\u00ednez-V\u00e9lez N, Garcia-Moure M, Marigil M,  The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235.10.1038\/s41467-019-10043-031138805"},{"issue":"12","key":"b19","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/nm.3013","article-title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors","volume":"18","author":"Alvarez-Breckenridge CA","year":"2012","unstructured":"Alvarez-Breckenridge CA, Yu J, Price R,  NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 2012;18(12):1827\u20131834.2317824610.1038\/nm.3013"},{"issue":"19","key":"b20","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"9398","DOI":"10.1158\/0008-5472.CAN-07-1063","article-title":"Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses","volume":"67","author":"Fulci G","year":"2007","unstructured":"Fulci G, Dmitrieva N, Gianni D,  Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 2007;67(19):9398\u20139406.10.1158\/0008-5472.CAN-07-106317909049"},{"issue":"23","key":"b21","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"12846","DOI":"10.1073\/pnas.97.23.12846","article-title":"Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas","volume":"97","author":"Aboody KS","year":"2000","unstructured":"Aboody KS, Brown A, Rainov NG,  Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23):12846\u201312851.10.1073\/pnas.97.23.1284611070094"},{"issue":"1","key":"b22","series-title":"Expert Rev Neurother","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/14737175.6.1.1","article-title":"Targeted therapy for malignant glioma: neural stem cells","volume":"6","author":"Lesniak MS","year":"2006","unstructured":"Lesniak MS. Targeted therapy for malignant glioma: neural stem cells. Expert Rev Neurother. 2006;6(1):1\u20133.1646630510.1586\/14737175.6.1.1"},{"issue":"4","key":"b23","series-title":"J Clin Invest","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla J","year":"2019","unstructured":"Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Invest. 2019;129(4):1407\u20131418.10.1172\/JCI12228730829653"},{"issue":"23","key":"b24","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1158\/0008-5472.CAN-08-3873","article-title":"Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas","volume":"69","author":"Yong RL","year":"2009","unstructured":"Yong RL, Shinojima N, Fueyo J,  Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009;69(23):8932\u20138940.1992019910.1158\/0008-5472.CAN-08-3873"},{"issue":"3","key":"b25","series-title":"Stem Cells","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/stemcells.2007-0758","article-title":"Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma","volume":"26","author":"Sonabend AM","year":"2008","unstructured":"Sonabend AM, Ulasov IV, Tyler MA,  Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells. 2008;26(3):831\u2013841.1819223210.1634\/stemcells.2007-0758"},{"issue":"13","key":"b26","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/jnci\/djt141","article-title":"A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy","volume":"105","author":"Ahmed AU","year":"2013","unstructured":"Ahmed AU, Thaci B, Tobias AL,  A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst. 2013;105(13):968\u2013977.10.1093\/jnci\/djt14123821758"},{"issue":"2","key":"b27","series-title":"Gene Ther","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/gt.2008.165","article-title":"Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo","volume":"16","author":"Tyler MA","year":"2009","unstructured":"Tyler MA, Ulasov IV, Sonabend AM,  Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16(2):262\u2013278.1907899310.1038\/gt.2008.165"},{"issue":"11","key":"b28","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/mt.2013.179","article-title":"N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy","volume":"21","author":"Kim CK","year":"2013","unstructured":"Kim CK, Ahmed AU, Auffinger B,  N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol Ther. 2013;21(11):2063\u20132073.2388386310.1038\/mt.2013.179"},{"issue":"4","key":"b29","series-title":"Cytotherapy","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcyt.2017.02.002","article-title":"Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas","volume":"19","author":"Parker Kerrigan BC","year":"2017","unstructured":"Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy. 2017;19(4):445\u2013457.10.1016\/j.jcyt.2017.02.00228233640"},{"issue":"24","key":"b30","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"11499","DOI":"10.1158\/0008-5472.CAN-07-5312","article-title":"Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter","volume":"67","author":"Alonso MM","year":"2007","unstructured":"Alonso MM, Gomez-Manzano C, Bekele BN,  Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007;67(24):11499\u201311504.10.1158\/0008-5472.CAN-07-531218089777"},{"key":"b31","series-title":"Mol Ther Oncolytics","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.omto.2017.02.002","article-title":"The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8+T cell anti-tumor activity","volume":"5","author":"Kleijn A","year":"2017","unstructured":"Kleijn A, van den Bossche W, Haefner ES,  The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8+T cell anti-tumor activity. Mol Ther Oncolytics. 2017;5:11\u201319.10.1016\/j.omto.2017.02.00228480325"},{"issue":"16","key":"b32","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin J","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R,  Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u20131546.10.1056\/NEJMoa191083631562797"},{"issue":"3","key":"b33","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy TF","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR,  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477\u2013486.10.1038\/s41591-018-0337-730742122"},{"issue":"7","key":"b34","series-title":"JAMA Oncol","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon DA","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A,  Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003\u20131010.3243750710.1001\/jamaoncol.2020.1024"},{"issue":"1","key":"b35","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa AT","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A,  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84\u201388.10.1038\/nm151717159987"},{"issue":"7","key":"b36","series-title":"Trends Cancer","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan Q","year":"2020","unstructured":"Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605\u2013618.10.1016\/j.trecan.2020.02.02232610070"},{"issue":"1","key":"b37","series-title":"Brain Pathol","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1750-3639.2008.00234.x","article-title":"Genetically engineered mouse models of brain cancer and the promise of preclinical testing","volume":"19","author":"Huse JT","year":"2009","unstructured":"Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 2009;19(1):132\u2013143.10.1111\/j.1750-3639.2008.00234.x19076778"},{"issue":"1","key":"b38","series-title":"Cancer Gene Ther","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/cgt.2014.64","article-title":"A novel immunocompetent murine model for replicating oncolytic adenoviral therapy","volume":"22","author":"Zhang L","year":"2015","unstructured":"Zhang L, Hedjran F, Larson C,  A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Cancer Gene Ther. 2015;22(1):17\u201322.10.1038\/cgt.2014.6425525035"},{"issue":"4","key":"b39","series-title":"Cancer Gene Ther","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/cgt.2008.80","article-title":"Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats","volume":"16","author":"Sonabend AM","year":"2009","unstructured":"Sonabend AM, Ulasov IV, Han Y,  Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther. 2009;16(4):362\u2013372.10.1038\/cgt.2008.8019011597"},{"issue":"5","key":"b40","series-title":"PLoS One","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","author":"Jiang H","year":"2014","unstructured":"Jiang H, Clise-Dwyer K, Ruisaard KE,  Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014;9(5):e97407."},{"issue":"12","key":"b41","series-title":"Cell Rep","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.celrep.2019.02.063","article-title":"Modeling patient-derived glioblastoma with cerebral organoids","volume":"26","author":"Linkous A","year":"2019","unstructured":"Linkous A, Balamatsias D, Snuderl M,  Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep. 2019;26(12):3203\u20133211.e5.10.1016\/j.celrep.2019.02.06330893594"},{"issue":"7","key":"b42","series-title":"Cell","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal JT","year":"2018","unstructured":"Neal JT, Li X, Zhu J,  Organoid modeling of the tumor immune microenvironment. Cell. 2018;175(7):1972\u20131988.e16.10.1016\/j.cell.2018.11.02130550791"},{"issue":"505","key":"b43","series-title":"Sci Transl Med","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca EA","year":"2019","unstructured":"Chiocca EA, Yu JS, Lukas RV,  Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019;11(505):eaaw5680.3141314210.1126\/scitranslmed.aaw5680"},{"issue":"5","key":"b44","series-title":"PLoS One","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097495","article-title":"The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity","volume":"9","author":"Kleijn A","year":"2014","unstructured":"Kleijn A, Kloezeman J, Treffers-Westerlaken E,  The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS One. 2014;9(5):e97495.10.1371\/journal.pone.009749524866126"},{"issue":"3","key":"b45","series-title":"Biomedicines","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3390\/biomedicines4030013","article-title":"Tumor-associated macrophages in oncolytic virotherapy: friend or foe?","volume":"4","author":"Denton NL","year":"2016","unstructured":"Denton NL, Chen CY, Scott TR, Cripe TP. Tumor-associated macrophages in oncolytic virotherapy: friend or foe? Biomedicines. 2016;4(3):E13.10.3390\/biomedicines4030013"},{"key":"b46","article-title":"DNX-2401 with Interferon Gamma (IFN-\u03b3) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)","author":"Lang FF","unstructured":"Lang FF. DNX-2401 with Interferon Gamma (IFN-\u03b3) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I). Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02197169"},{"key":"b47","article-title":"Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM)","author":"Tejada S","unstructured":"Tejada S. Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM). Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01956734"},{"key":"b48","article-title":"Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients with Recurrent Glioblastoma","author":"Dirven C","unstructured":"Dirven C. Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients with Recurrent Glioblastoma. Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01582516"},{"key":"b49","article-title":"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas","author":"Gallego J","unstructured":"Gallego J. Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas. Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03178032"},{"key":"b50","article-title":"Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)","author":"Zadeh G","unstructured":"Zadeh G. Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02798406"},{"key":"b51","article-title":"Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma","author":"Lang FF","unstructured":"Lang FF. Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma. Accessed December 16, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0389656829432077"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/50\/2\/article-pE6.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/50\/2\/article-pE6.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/50\/2\/article-pE6.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:20:36Z","timestamp":1779524436000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/50\/2\/article-pE6.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":102,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2020.11.focus20853","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}